Drawing for ACQUINET

USPTO serial 99106752

ACQUINET

Reviewed by CopyMark Law Group

Status 730Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
MORRIS, ALINA S.
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 730: Status 730 means you filed the first six-month extension to delay filing a Statement of Use after a Notice of Allowance. You must file a Statement of Use or another extension before the new deadline.

Need help with ACQUINET?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $249*

Plus Government fees of $150

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Julia Anne Matheson

Julia Anne Matheson Potomac Law Group, PLLC1717 Pennsylvania Avenue, NW, Suite 1025Washington, DC 20006United States

Goods and services

ClassDescriptionStatusFirst use
005Therapeutic drug delivery agents being compounds containing resonators that facilitate the delivery of pharmaceutical preparations and monitoring thereof for use in connection with medical ultrasound apparatus to facilitate the lowering of the blood brain barrier; Therapeutic drug delivery agents being compounds containing resonators that facilitate the delivery of pharmaceutical preparations and monitoring thereof for use in connection with medical ultrasound apparatus to facilitate the disruption of the blood brain barrier; Therapeutic drug delivery agents being compounds containing resonators that facilitate the delivery of pharmaceutical preparations and monitoring thereof for use in connection with medical ultrasound apparatus to increase the permeability of the blood brain barrier; Therapeutic drug delivery agents being compounds containing resonators that facilitate the delivery of pharmaceutical preparations and monitoring thereof to be used in connection with ultrasound apparatus for therapeutic and diagnostic medical procedures in the fields of neurology, oncology, gynecology and urology; Therapeutic drug delivery agents being compounds containing resonators that facilitate the delivery of pharmaceutical preparations and monitoring thereof to be used in connection with ultrasound apparatus for therapeutic and diagnostic medical procedures with respect to central nervous system disorders, neurodegenerative disease, neuro-oncological disease, neuropsychiatric and behavioral disorders, movement disorders, prostate cancer, uterine fibroids and bone metastases; Therapeutic drug delivery agents being compounds containing resonators that facilitate the delivery of pharmaceutical preparations and monitoring thereof to be used in connection with ultrasound apparatus for therapeutic and diagnostic medical procedures, namely, for use in the ablation of tissue, sonication of tissue, and disruption of the blood brain barrierACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 21, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 21, 2026EX1GSOU EXTENSION 1 GRANTED—
Apr 21, 2026EXT1SOU EXTENSION 1 FILED—
Apr 21, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 16, 2025NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Oct 21, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 21, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 15, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 24, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 24, 2025XAECEXAMINER'S AMENDMENT ENTERED—
Sep 24, 2025GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 24, 2025GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 24, 2025CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 26, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 26, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 26, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 26, 2025DOCKASSIGNED TO EXAMINER—
Jul 11, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 27, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 27, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance